Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera

Recently, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage called B.1.1.7 (variant of concern: VOC 202012/01), which is reported to spread more efficiently and faster than other strains, emerged in the United Kingdom. This variant has an unusually large number of mutations,...

Full description

Saved in:
Bibliographic Details
Published in:Science 2021-03, Vol.371 (6534), p.1152-1153
Main Authors: Muik, Alexander, Wallisch, Ann-Kathrin, Sänger, Bianca, Swanson, Kena A, Mühl, Julia, Chen, Wei, Cai, Hui, Maurus, Daniel, Sarkar, Ritu, Türeci, Özlem, Dormitzer, Philip R, Şahin, Uğur
Format: Article
Language:English
Subjects:
Adult
Aged
Amino acid sequence
Amino acids
Antibodies
Antibodies, Neutralizing - blood
Antibodies, Viral - blood
Antisera
China
Coronaviridae
Coronaviruses
COVID-19
COVID-19 - blood
COVID-19 - prevention & control
COVID-19 - virology
COVID-19 vaccines
COVID-19 Vaccines - immunology
Female
Humans
Immunization
Infectivity
Male
Medicine
Microbio
Middle Aged
mRNA
Mutation
Neutralization
Neutralization Tests
Neutralizing
Proteins
Respiratory diseases
SARS-CoV-2 - genetics
SARS-CoV-2 - immunology
Severe acute respiratory syndrome coronavirus 2
Spike Glycoprotein, Coronavirus - genetics
Spike Glycoprotein, Coronavirus - immunology
Spike protein
United Kingdom
Vaccines
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recently, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage called B.1.1.7 (variant of concern: VOC 202012/01), which is reported to spread more efficiently and faster than other strains, emerged in the United Kingdom. This variant has an unusually large number of mutations, with 10 amino acid changes in the spike (S) protein, raising concerns that its recognition by neutralizing antibodies may be affected. In this study, we tested SARS-CoV-2-S pseudoviruses bearing either the Wuhan reference strain or the B.1.1.7 lineage spike protein with sera of 40 participants who were vaccinated in a previously reported trial with the messenger RNA-based COVID-19 vaccine BNT162b2. The immune sera had slightly reduced but overall largely preserved neutralizing titers against the B.1.1.7 lineage pseudovirus. These data indicate that the B.1.1.7 lineage will not escape BNT162b2-mediated protection.
ISSN:0036-8075
1095-9203
DOI:10.1126/science.abg6105